Who’s Hired? ANI Names New CEO

ANI Pharmaceuticals Picks New Chief As Teva and Mylan Make Moves

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

ANI Pharmaceuticals has chosen its new president and CEO to replace interim chief Patrick Walsh who stepped in after the departure Arthur Przybyl earlier this year. Meanwhile, key personnel announcements have also been made by Teva and Mylan.

Team_Leader
ANI Pharmaceuticals has selected a new leader • Source: Shutterstock

ANI Pharmaceuticals has named Cipla USA chief executive Nikhil Lalwani to become its new president and CEO from 8 September. Lalwani – who will join ANI’s board on the same date – will replace interim president and CEO Patrick Walsh, who had stepped in after the departure of former chief Arthur Przybyl earlier this year. (Also see "ANI Names Interim CEO As Przybyl Prepares To Step Down" - Generics Bulletin, 8 May, 2020.)

“We are delighted to welcome Nikhil to ANI Pharmaceuticals,” said Walsh. “With his proven ability to create high-growth cultures and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Leadership

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C5

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C4

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.